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ABSTRACT
Several professional organizations have recommended tramadol as one of the first-line or second-line therapies for patients with
chronic noncancer pain and its prescription has been increasing rapidly worldwide; however, the safety profile of tramadol, such
as risk of fracture, remains unclear. This study aimed to examine the association of tramadol with risk of hip fracture. Among individ-
uals age 50 years or older without a history of hip fracture, cancer, or opioid use disorder in The Health Improvement Network (THIN)
database in the United Kingdomgeneral practice (2000–2017), five sequential propensity score–matched cohort studies were assem-
bled, ie, participants who initiated tramadol or those who initiated one of the following medications: codeine (n = 146,956) (another
commonly used weak opioid), naproxen (n = 115,109) or ibuprofen (n = 107,438) (commonly used nonselective nonsteroidal anti-
inflammatory drugs [NSAIDs]), celecoxib (n = 43,130), or etoricoxib (n = 27,689) (cyclooxygenase-2 inhibitors). The outcome was inci-
dent hip fracture over 1 year. After propensity-score matching, the included participants had a mean age of 65.7 years and 56.9%
were women. During the 1-year follow-up, 518 hip fracture (3.7/1000 person-years) occurred in the tramadol cohort and
401 (2.9/1000 person-years) occurred in the codeine cohort. Compared with codeine, hazard ratio (HR) of hip fracture for tramadol
was 1.28 (95% confidence interval [CI] 1.13 to 1.46). Risk of hip fracture was also higher in the tramadol cohort than in the naproxen
(2.9/1000 person-years for tramadol, 1.7/1000 person-years for naproxen; HR = 1.69, 95% CI 1.41 to 2.03), ibuprofen (3.4/1000 person-
years for tramadol, 2.0/1000 person-years for ibuprofen; HR = 1.65, 95%CI 1.39 to 1.96), celecoxib (3.4/1000 person-years for tramadol,
1.8/1000 person-years for celecoxib; HR = 1.85, 95% CI 1.40 to 2.44), or etoricoxib (2.9/1000 person-years for tramadol, 1.5/1000
person-years for etoricoxib; HR = 1.96, 95% CI 1.34 to 2.87) cohort. In this population-based cohort study, the initiation of tramadol
was associated with a higher risk of hip fracture than initiation of codeine and commonly used NSAIDs, suggesting a need to revisit
several guidelines on tramadol use in clinical practice. © 2020 American Society for Bone and Mineral Research.
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Introduction
I n the general population aged 50 years and older, about 20%of men and 50% of women are likely to sustain at least one
fracture during the remainder of their lives, which often results
in increased morbidity and mortality.(1,2) The health care burden
related to fracture is expected to double by 2025.(3–5) Polyphar-
macy is common among elderly patients due to multiple comor-
bidities, and some medications may intensify the risk of fracture,
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either through their effect on increasing fall risk and/or through
an effect on bone metabolism.(6–9)
Tramadol, a commonly used weak opioid for the treatment of
pain,(10–14) has been considered an analgesic alternative, since its
perceived risk of serious cardiovascular and gastrointestinal
adverse effects was lower than that of nonsteroidal anti-
inflammatory drugs (NSAIDs),(15,16) and its risk of addiction and
respiratory depression was lower than that of traditional opi-
oids.(17,18) As a result, tramadol use has been increasing rapidly
worldwide over the past decades.(10–14) For example, data from
Truven Health Analytics MarketScan in the United States showed
that prescriptions of tramadol increased by 22.8% between 2012
and 2015,(10) and tramadol dispensing rates increased in each of
the provinces in Canada, with the highest in Nova Scotia increas-
ing from 0.50/defined daily doses (DDD) in 2007 to 2.64/DDD in
2016.(11)
Nevertheless, a recently published population-based cohort
study reported a significantly higher all-cause mortality rate with
tramadol use than with commonly used NSAIDs among patients
with osteoarthritis;(14) however, the specific mechanisms linking
tramadol use to an increased risk of mortality remains unclear. To
date, several studies have reported that tramadol use might
increase the risk of falls (a strong risk factor for fracture),(19–22)
but only a few studies have addressed the potential relationship
between tramadol use and the risk of fracture, and the results are
inconclusive.(23–25) Furthermore, few, if any, studies have com-
pared the risk of hip fracture, one that ranks among the top
10 leading causes of disability globally,(26,27) among tramadol ini-
tiators with that among initiators of other commonly used
analgesics.
To fill this knowledge gap, we compared the risk of incident
hip fracture among tramadol initiators with the initiators of one
of the following medications: codeine (another commonly used
weak opioid), naproxen or ibuprofen (commonly used nonselec-
tive NSAIDs), celecoxib, or etoricoxib (cyclooxygenase-2 [COX-2]
inhibitors) by conducting five propensity score–matched cohort
studies.
Materials and Methods
Data source
This study was based on the data retrieved from The Health
Improvement Network (THIN), which contains medical records
of about 17 million individuals from 770 general practices in
the United Kingdom (UK). In THIN, the following data were
recorded for each patient: anthropometrics, sociodemographics,
lifestyle habits, general practitioner (GP) visit details, diagnoses
from specialists’ evaluations and hospital admissions, as well as
laboratory testing results. All the diagnoses in THIN were coded
by the Read classification system,(28) while the medications were
coded by Multilex classification system.(29) Previous studies have
demonstrated that THIN data were valid for both epidemiologi-
cal and clinical studies.(30)
Study design and cohort definition
Included in this analysis were participants who were 50 years or
older between January 2000 and December 2016 and had not
been prescribed tramadol or its active comparator (ie, codeine,
naproxen, ibuprofen, celecoxib, or etoricoxib) over 1 year or
more before entering this study. Individuals who had a history
of hip fracture, cancer, or opioid use disorder before entry into
this study cohort were excluded.
We compared the risk of incident hip fracture between partic-
ipants who initiated tramadol and those who initiated one of the
following pain-relief medications: codeine (another commonly
used weak opioid), naproxen or ibuprofen (commonly used non-
selective NSAIDs), celecoxib, or etoricoxib (COX-2 inhibitors). The
index date is defined as the date of initiating either tramadol or
the comparator for the corresponding participants. The total
time interval from January 2000 to December 2016 was divided
into 17 1-year blocks. Within each time block, we identified tra-
madol or the comparator initiators and calculated the propensity
score for tramadol initiation using logistic regression. Propensity
score is defined as the probability of treatment assignment con-
ditional on observed baseline characteristics,(31) which can be
calculated based on the following variables: age at index date,
sex, Townsend deprivation index,(32) body mass index (BMI),
alcohol drinking habits, smoking status, comorbidities and med-
ication use before the index date, and health care utilization (ie,
number of hospitalizations, general practice visits, and specialist
referrals) during the past year before the index date (variables
listed in Table 1). Within each time block, tramadol initiators were
matched 1:1 to the comparator initiators using the greedy-
matching algorithm, ie, for each tramadol initiator, a comparator
initiator with the closest propensity score was selected.(31) Pro-
pensity score matching is used to balance many covariates in
epidemiological studies and to reduce the effect of confounding
by indication.(31) We adopted this method to assemble five pro-
pensity score–matched cohort studies: tramadol versus codeine,
tramadol versus naproxen, tramadol versus ibuprofen, tramadol
versus celecoxib, and tramadol versus etoricoxib, respectively.
Assessment of outcome
The incident hip fracture during a 1-year follow-up period was
the primary outcome of the study. Hip fracture was identified
by using Read Codes as previous studies have done in
THIN.(33–35)
Statistical analysis
The baseline characteristics of the tramadol cohort were com-
pared with that of each of the active comparison cohorts, ie,
codeine, naproxen, ibuprofen, celecoxib, or etoricoxib cohort.
We adopted an “intention-to-treat” analysis method to compute
the follow-up time for each participant, while person-years of
follow-up for each participant were calculated as the time frame
from the index date to the earliest occurrence of the following:
incident hip fracture, disenrollment from a GP practice, age of
90 years, death, or the end of 1 year follow-up. We computed
the rate of incident hip fracture for each cohort and plotted
cumulative incidence curves of hip fracture. We calculated the
absolute rate difference (RD) in incident hip fracture between
the tramadol cohort and each of the active comparison cohorts
according to the following formula: RD = rate (tramadol) – rate
(comparison). The hazard ratio (HR) of incident hip fracture for
the tramadol initiation was obtained using cause-specific Cox
proportional hazard models accounting for the competing risk
of death when compared with each comparator.(36) We per-
formed the sex-specific analyses to test whether the relation of
tramadol initiation to the risk of hip fracture inmen differed from
that in women.
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Table 1. Basic Characteristics of Tramadol Cohort Compared With Codeine Cohort
Before propensity score matching Propensity score matched
Tramadol Codeine
Standard
difference Tramadol Codeine
Standard
difference
Participants (n) 202,003 170,369 146,956 146,956
Demographics
Age, mean (SD) (years) 65.9 (10.0) 67.1 (10.3) 0.112 66.5 (10.1) 66.5 (10.1) 0.001
Socioeconomic deprivation
index, mean (SD)1
2.8 (1.4) 2.6 (1.3) 0.122 2.7 (1.3) 2.7 (1.3) 0.001
Female (%) 57.5 57.9 0.009 57.4 57.5 0.001
BMI, mean (SD) (kg/m2) 28.5 (5.8) 27.8 (5.4) 0.126 28.1 (5.5) 28.1 (5.5) 0.001
Lifestyle factors
Drinking (%) 0.030 0.002
None 21.1 19.9 20.1 20.2
Past 3.0 2.9 2.8 2.8
Current 75.9 77.2 77.1 77.0
Smoking (%) 0.132 0.003
None 47.2 52.0 50.3 50.4
Past 31.8 31.9 32.1 32.1
Current 20.9 16.1 17.6 17.5
Comorbidity (%)
Other fracture2 8.3 7.7 0.022 7.9 7.8 0.001
Fall 11.2 12.6 0.044 11.9 11.8 <0.001
Osteoporosis 9.0 7.9 0.038 8.2 8.2 0.001
Seizure 0.6 0.7 0.010 0.6 0.6 0.001
Diabetes 15.2 14.9 0.009 14.8 14.8 0.001
Hypertension 45.8 46.4 0.010 46.0 46.1 0.001
Liver disease 2.5 2.5 0.001 2.5 2.5 0.001
Chronic kidney disease 8.3 9.2 0.033 8.7 8.7 0.001
Transient ischemic attack 3.2 3.5 0.013 3.3 3.3 0.001
Ischemic heart disease 16.6 16.0 0.018 16.1 16.0 0.002
Congestive heart failure 3.6 3.9 0.017 3.6 3.6 0.001
Myocardial infarction 6.5 6.3 0.007 6.4 6.3 0.001
Stroke 4.0 4.4 0.025 4.1 4.1 0.001
Angina 10.5 10.2 0.010 10.2 10.2 <0.001
Peripheral vascular disease 2.4 1.8 0.044 2.0 2.0 0.003
Venous thromboembolism 3.6 3.3 0.014 3.4 3.4 0.001
Pneumonia or infection 7.4 7.4 0.002 7.4 7.3 0.001
Hyperlipidemia 15.3 14.6 0.020 14.7 14.8 0.001
Dementia 0.7 1.4 0.074 0.8 0.9 0.002
Varicose veins 10.2 10.3 0.001 10.3 10.3 0.001
Other circulatory disease 28.3 28.8 0.010 28.6 28.5 0.001
Osteoarthritis 33.9 28.5 0.116 30.4 30.5 0.001
Rheumatoid arthritis 2.8 1.9 0.057 2.2 2.1 0.004
Depression 15.1 13.0 0.062 13.5 13.5 0.001
Chronic obstructive pulmonary disease 7.2 6.0 0.046 6.4 6.3 0.003
Atrial fibrillation 5.3 6.4 0.046 5.8 5.8 <0.001
Anxiety 15.8 15.0 0.023 15.1 15.1 <0.001
Sleep disorder or sleep apnea 1.9 1.6 0.020 1.7 1.7 <0.001
Peptic ulcer 7.8 6.6 0.047 7.0 6.9 0.003
Alcohol abuse 3.6 2.6 0.058 2.8 2.8 0.002
Medication (%)
Other opioids3 19.0 11.0 0.227 12.8 12.4 0.010
Other NSAIDs3 79.1 69.9 0.212 74.5 74.7 0.005
Aspirin 34.9 34.2 0.016 34.2 34.0 0.003
Bisphosphonates 8.1 6.7 0.052 7.1 7.0 0.004
Statin 40.6 38.2 0.050 38.8 38.8 <0.001
Glucocorticoids 23.6 21.7 0.047 22.4 22.2 0.005
Nitrates 15.4 14.4 0.028 14.6 14.5 0.003
(Continues)
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A total of seven sensitivity analyses were performed to test the
robustness of findings. First, we excluded the participants with a
propensity score above the 97.5th percentile of the propensity
score of the comparator cohort and below the 2.5th percentile
of the propensity score of the tramadol cohort.(37) Second, we
restricted our analyses to the participants who were not pre-
scribed other opioids before index date to minimize the residual
confounding effect by indication. Third, we performed missing
data imputation analyses and imputed five data sets in total.
We calculated the effect estimates and their confidence intervals
(CIs) from each imputed dataset. Then, we calculated the overall
effect estimate and its confidence intervals from five imputed
data sets using Rubin’s rules.(38) Fourth, we performed an “as-
treated” analysis to account for nonadherence of medications
under investigation throughout study period. Specifically, indi-
viduals were followed from the index date until the earliest
occurrence of the following: an incident hip fracture, disenroll-
ment from a GP practice, age of 90 years, death, the end of a
1-year follow-up period, drug discontinuation, or change of initi-
ated medication (eg, swapping from tramadol to codeine or vice
versa, while comparing the two). If a participant had not refilled a
prescription for a period of more than 60 days,(39) the follow-up
time would be censored at that time. Fifth, we conducted quan-
titative sensitivity analyses to evaluate the minimum unmea-
sured confounding effect that would explain away an
association observed in previous analyses.(40) Sixth, we con-
ducted a sensitivity analysis for atraumatic hip fracture. Specifi-
cally, the atraumatic hip fracture was considered as the
outcome, and cause-specific Cox proportional hazard models
accounting for the competing risk of death were performed
when compared with each comparison cohort. Lastly, we per-
formed a sensitivity analysis restricted to individuals aged
60 years or older.
All statistical analyses were performed on SAS v. 9.4 (SAS Insti-
tute, Cary, NC, USA) with p < 0.05 as statistical significance.
Results
Of 3,755,932 patients who met the inclusion criteria, 612,981
patients initiated with either tramadol (n = 337,167) or codeine
(n = 275,814) treatment without prescription history of both
drugs before entering this study. We excluded 102,483 patients
who had a history of cancer, opioid use disorder, or hip fracture,
and 138,126 patients who had missing information on BMI,
smoking status, alcohol drinking, or Townsend deprivation index
score. Of the remaining (n = 372,372), 146,956 initiators of trama-
dol (72.7%) were matched to the same number of initiators of
codeine by propensity score (Fig. 1). The selection process for
the other four propensity score–matched cohorts is illustrated
in the Supplemental Material.
The baseline characteristics of each before and after propen-
sity score–matched cohort are presented in Table 1 and Supple-
mental Material. The mean age was between 65.0 and 66.5 years
in different propensity score–matched cohorts, and approxi-
mately 60% were women. Overall, the characteristics across the
Table 1. Continued
Before propensity score matching Propensity score matched
Tramadol Codeine
Standard
difference Tramadol Codeine
Standard
difference
Antihypertensive medicine 64.7 63.1 0.035 63.4 63.4 <0.001
Antidiabetic medicine 11.5 10.9 0.017 11.1 11.0 0.001
ACE inhibitors 34.3 34.8 0.010 34.5 34.5 0.001
Beta receptor inhibitors 35.2 35.3 0.001 35.1 35.1 <0.001
Calcium channel blockers 32.0 31.3 0.015 31.4 31.3 0.001
Loop diuretics 19.2 17.5 0.044 17.7 17.6 0.002
Thiazide diuretics 33.0 32.7 0.006 32.7 32.8 0.001
Potassium-sparing diuretics 8.5 7.6 0.034 7.8 7.7 0.003
Angiotensin receptor blocker 12.4 12.0 0.011 12.3 12.0 0.009
Insulin 3.4 3.0 0.019 3.1 3.1 <0.001
Anticoagulants 7.1 7.8 0.025 7.4 7.3 0.001
Benzodiazepines 41.0 32.5 0.178 35.2 35.1 0.002
SSRI 26.8 22.0 0.113 23.2 23.2 <0.001
SNRI 7.9 5.7 0.085 6.2 6.2 0.002
Antiepileptic medicine 10.7 7.5 0.112 8.3 8.2 0.004
Estrogen 19.2 18.0 0.029 18.5 18.6 0.002
PPIs 54.0 46.7 0.148 49.3 49.2 0.003
H2 blockers 24.7 21.5 0.076 22.7 22.5 0.005
Health care utilization, mean (SD)
Hospitalizations4 0.5 (1.2) 0.4 (1.1) 0.037 0.4 (1.1) 0.4 (1.1) 0.005
General practice visits4 7.2 (6.6) 6.9 (6.5) 0.045 7.0 (6.6) 7.0 (6.4) 0.003
Specialist referrals4 0.6 (1.1) 0.5 (1.0) 0.095 0.6 (1.0) 0.6 (1.0) 0.004
BMI = body mass index; SD = standard deviation; NSAID = nonsteroidal anti-inflammatory drug; ACE = angiotensin converting enzyme; SSRI = selective
serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor; PPIs = proton pump inhibitor; H2 blockers = histamine-2 blockers.
1 The socioeconomic deprivation index (ie, Townsend deprivation index) was grouped into quintiles from 1 (least deprived) to 5 (most deprived).
2 Other fracture refers to spine and wrist fracture.
3 Other NSAIDs or opioids means other NSAID or opioid use before the index date.
4 Frequency during the past 1 year.
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propensity score–matched cohorts were balanced, with all of the
standardized differences <0.1.(41)
The tramadol cohort had a higher risk of incident hip fracture
than did the codeine cohort (Fig. 2). As shown in Table 2, a total
of 518 cases of hip fracture (3.7/1000 person-years) were
reported in the tramadol cohort and 401 cases (2.9/1000
person-years) were reported in the codeine cohort during the
1-year follow-up. The RD of incident hip fracture in the tramadol
cohort versus that in the codeine cohort was 0.8 (95% CI 0.4 to
1.2)/1000 person-years and the corresponding HR was 1.28
(95% CI 1.13 to 1.46) (Fig. 3). Meanwhile, the tramadol cohort also
exhibited a higher risk of incident hip fracture than did the
codeine cohort among both the female (HR = 1.18, 95% CI 1.02
to 1.38) and male subgroup (HR = 1.60, 95% CI 1.24 to 2.06)
(Fig. 3; RDs are shown in the Supplemental Material). The results
of sensitivity analyses (ie, propensity-score trimming, restricting
analyses among the participants without history of other opioid
use, missing data imputation, “as-treated” approach, or restrict-
ing outcome to atraumatic hip fracture) did not change materi-
ally (Supplemental Material). Furthermore, according to the
quantitative sensitivity analyses, the observed association (ie,
HR = 1.28) might be explained by the residual confounding
effect if there is an unmeasured covariate with HR ≥ 1.88 with
both tramadol use and risk of hip fracture.
The tramadol cohort also had a higher risk of incident hip frac-
ture than did either the naproxen (Fig. 4A) or the ibuprofen
(Fig. 4B) cohort. As shown in Table 3, a total of 313 cases of inci-
dent hip fracture (2.9/1000 person-years) were reported in the
tramadol cohort and 185 (1.7/1000 person-years) cases were
reported in the naproxen cohort. Relative to naproxen initiation,
the HR of hip fracture for initiation of tramadol was 1.69 (95% CI
1.41 to 2.03) (Fig. 3) and the corresponding RD was 1.2 (95% CI
Fig. 1. Selection process of propensity score–matched cohorts of patients with noncancer pain and tramadol initiation compared with initiation of
codeine.
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0.8 to 1.6)/1000 person-years (Table 3). Similarly, the risk of inci-
dent hip fracture was also higher in the tramadol cohort
(3.4/1000 person-years) than in the ibuprofen cohort (2.0/1000
person-years) (HR = 1.65, 95% CI 1.39 to 1.96) (Table 3 and Fig. 3).
Results from sex subgroup analyses (Fig. 3, Supplemental Mate-
rial) and several sensitivity analyses did not change materially
(Supplemental Material).
The risk of incident hip fracture was higher in the tramadol
cohort than in either the celecoxib cohort (3.4/1000 person-years
versus 1.8/1000 person-years) (Fig. 4C) or the etoricoxib cohort
(2.9/1000 person-years versus 1.5/1000 person-years) (Fig. 4D).
The RDs of incident hip fracture for the tramadol cohort were
1.6 (95% CI 0.9 to 2.3) and 1.5 (95% CI 0.7 to 2.3)/1000 person-
years, compared with the celecoxib and the etoricoxib cohorts,
respectively (Table 3). The corresponding HRs were 1.85 (95%
CI 1.40 to 2.44) and 1.96 (95% CI 1.34 to 2.87), respectively
(Fig. 3). The results of sex subgroup analyses (Fig. 3, Supplemen-
tal Material) and sensitivity analyses (Supplemental Material)
remained similar.
In addition, according to the quantitative sensitivity analyses,
the relation (ie, HR) of potential residual confounder(s) to both
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Fig. 2. Time to incident hip fracture for the propensity score–matched
cohorts of patients with noncancer pain and tramadol initiation compar-
ied with initiation of codeine.
Table 2. Incident Hip Fracture Within 1 Year Among Patients Ini-
tiating Tramadol Compared With Initiation of Another Com-
monly Used Weak Opioid (Codeine)
Weak opioid
Tramadol versus codeine
Participants (n) 146,956 146,956
Incident hip fracture (n) 518 401
Mean follow-up (years) 0.95 0.94
Rate (/1000 person-years)1 3.7 2.9
RD (/1000 person-years, 95% CI) 0.8 (0.4, 1.2) 0.0
(reference)
RD = rate difference; CI = confidence interval.
1 Number (rate) of competing event (ie, death) in tramadol and codeine
group was 5449 (39.2/1000 person-years) and 4984 (36.0/1000
person-years), respectively.
Fig. 3. Forest plot of hazard ratios and related 95% confidence intervals of hip fracture for the propensity score–matched cohorts of patients with non-
cancer pain and tramadol initiation compared with initiation of codeine, naproxen, ibuprofen, celecoxib, or etoricoxib.
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tramadol initiation and incident hip fracture needs to be ≥2.69 in
order to completely explain away the weakest association
observed in our primary analyses of comparison of tramadol ini-
tiators with NSAIDs initiators (ie, HR = 1.65 for tramadol initiators
versus ibuprofen initiators).
Discussion
This population-based cohort study, utilizing a relatively large
sample, found that the initiation of tramadol involved a
higher risk of incident hip fracture than did the initiation of
either a commonly used weak opioid (ie, codeine) or com-
monly used NSAID (ie, naproxen, ibuprofen, celecoxib, and
etoricoxib). The sensitivity analyses had similar results, indi-
cating that the observed associations were robust and raising
a concern on the potential risk of hip fracture among initiators
of tramadol use.
Comparison with previous studies
To date, tramadol has become one of the most commonly used
pain-relief medications around the world; however, to our
knowledge, its safety profile, such as risk of fracture, remains
unclear. Several studies have examined the association between
tramadol use and the risk of fracture in various settings, but the
results are conflicting.(23–25) One case–control study based on
the data retrieved from the Denmark national registry reported
that tramadol users had an approximately 55% higher risk of
fracture at the hip, forearm, or spine than non-users; however,
the corresponding association with codeine users was much
weaker (odds ratio [OR] = 1.16).(23) Similarly, a study from the
UK General Practice Research Database suggested that the cur-
rent use of tramadol (OR = 1.25) or codeine (OR = 1.20) versus
non-use was associated with an increased risk of fracture at
either hip, humerus, or wrist.(25) Unfortunately, these findings
are likely to be susceptible to the potential confounding by indi-
cation because both studies used non-users as a comparison
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Fig. 4. Time to incident hip fracture for the propensity score–matched cohorts of patients with noncancer pain and tramadol initiation compared with
initiation of naproxen (A), ibuprofen (B), celecoxib (C), or etoricoxib (D).
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group.(23,25) In a propensity score–matched cohort study using
the US Medicare database, the authors claimed that the inci-
dence of fracture at hip, pelvis, wrist, and humerus was lower
in tramadol initiators (7/100 person-years) than that in codeine
initiators (27/100 person-years) during the 180-day follow-up
period.(24) However, the study was unable to adjust for body
mass index, smoking, and alcohol use due to lack of information
from the database.(24) Second, the two important demographic
factors for fracture are substantially different in these two stud-
ies. In the previously published study,(24) the average age of sub-
jects was approximately 80 years and 80% were women. In our
study, the average age was 65 years and 66% were women. Fur-
thermore, the study did not specifically evaluate the association
of tramadol initiation with the risk of hip fracture, a disease that is
often associated with the worse consequence, such as disability
and death.(26,27) As a result (ie, different study population, differ-
ent outcome variable), the incidence rate of fracture in their
study was much higher than ours (270 per 1000 person-years
versus 2.9 per 1000 person-years in the codeine cohort; 70 per
1000 person-years versus 3.7 per 1000 person-years in tramadol
cohort).(24) Our study demonstrated that the risk of hip fracture
among tramadol initiators is not only higher than that among
NSAIDs initiators but also higher than that among codeine
(another weak opioid) initiators. Further studies that evaluate
the potential mechanisms, such as whether tramadol use
increases the risk of osteoporosis or risk of fall, will help us better
elaborate the association between tramadol use and the risk of
hip fracture.
Possible explanations
Previous studies have found that tramadol could activate μ opi-
oid receptors and suppress central serotonin and norepineph-
rine reuptake, resulting in seizures,(18) dizziness,(42,43) and/or
delirium.(44) Subsequently, such side effects may cause an
increased risk of fall. In fact, several studies have reported that
tramadol use was indeed associated with a higher risk of fall,
which is a critical risk factor for fracture.(19–22) All these studies
appear to suggest that relation of tramadol to the risk of hip frac-
ture may be, at least partly, through its effect on fall.
Strengths and limitations
Several characteristics of the present study deserve comment.
First, using a population-based cohort study, we found that the
risk of incident hip fracture among tramadol initiators was not
only higher than that among NSAIDs initiators but also higher
than that among codeine initiators, suggesting that the con-
founding by indication may not substantially account for an
increased risk of hip fracture for tramadol. This was further sup-
ported by the evidence that risk factor profiles between initial
prescription of tramadol and that of codeine were similar even
before propensity matching, except a few (eg, BMI was higher
among tramadol than codeine prescriptions) that may lower
the risk of fracture for tramadol. Nevertheless, as in all observa-
tional studies, we cannot rule out the impact of potential residual
confounders when comparing the risk of hip fracture between
initial prescription of tramadol and other pain-relief medications.
Second, we adopted a new-user design to compare the risk of
hip fracture among tramadol initiators with initiators of several
commonly used pain-relief medications. This design minimizes
the potential selection bias. Third, because THIN does not
include bone density or any frailty measurements, these two
potential confounders could not be adjusted for in our analysis.
Fourth, administrative data are often lacking in information of
over-the-counter medications use (eg, NSAIDs); thus, the expo-
sure assessment is susceptible to misclassification bias. Such
bias, if occurs, would affect the observed association either
toward the null (ie, stop taking tramadol but taking the over-
the-counter NSAIDs) or away the null (ie, taking tramadol and
over-the-counter NSAIDs at the same time). Since the National
Health Service England provides free health care for most ser-
vices, including medications, ordered by GPs to individuals aged
60 years or older, it is unlikely that most patients would purchase
these drugs over-the-counter without a prescription. In a sensi-
tivity analysis restricted to individuals aged 60 years or older,
Table 3. Incident Hip Fracture Within 1 Year Among Patients Initiating Tramadol Compared With Initiation of One of Two Commonly
Used Nonselective NSAIDs (Naproxen, Ibuprofen) or One of Two Cyclooxygenase-2 Inhibitors (Celecoxib, Etoricoxib)
Nonselective NSAIDs
Tramadol versus naproxen Tramadol versus ibuprofen
Participants (n) 115,109 115,109 107,438 107,438
Incident hip fracture (n) 313 185 349 212
Mean follow-up (years) 0.95 0.96 0.95 0.96
Rate (/1000 person-years)1 2.9 1.7 3.4 2.0
RD (/1000 person-years, 95% CI) 1.2 (0.8, 1.6) 0.0 (reference) 1.4 (0.9, 1.8) 0.0 (reference)
Cyclooxygenase-2 inhibitors
Tramadol versus celecoxib Tramadol versus etoricoxib
Participants (n) 43,130 43,130 27,689 27,689
Incident hip fracture (n) 142 77 78 40
Mean follow-up (years) 0.96 0.98 0.96 0.98
Rate (/1000 person-years) 3.4 1.8 2.9 1.5
RD (/1000 person-years, 95% CI) 1.6 (0.9, 2.3) 0.0 (reference) 1.5 (0.7, 2.3) 0.0 (reference)
NSAIDs = nonsteroidal anti-inflammatory drugs; RD = rate difference; CI = confidence interval.
1 Number (rate) of competing event (ie, death) in comparison of tramadol and naproxen group was 3418 (31.2/1000 person-years) and 1431 (12.9/1000
person-years), in comparison of tramadol and ibuprofen group was 3958 (38.9/1000 person-years) and 1977 (19.1/1000 person-years), in comparison
of tramadol and celecoxib group was 1,776 (43.3/1000 person-years) and 751 (17.8/1000 person-years), in comparison of tramadol and etoricoxib
group was 877 (33.1/1000 person-years) and 366 (13.5/1000 person-years), respectively.
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we found that the relation of tramadol initiation to the risk of hip
fracture did not change materially when compared with other
pain-relief medications (tramadol versus codeine: HR = 1.28
(95% CI 1.12 to 1.47); tramadol versus naproxen: HR = 1.68
(95% CI 1.39 to 2.04); tramadol versus ibuprofen: HR = 1.67
(95% CI 1.39 to 1.99); tramadol versus celecoxib: HR = 1.75
(95% CI 1.32 to 2.32); tramadol versus etoricoxib: HR = 1.91
(95% CI 1.28 to 2.84), suggesting the impact of over-the-counter
NSAID use may not be substantial. In addition, most patients
who took pain-relief medication often change their initiated
treatment; thus, hip fracture could occur after subjects stopped
or changed their medication. Thus, estimates would be larger
from “as-treated” analysis than “intention-to-treat analysis” due
to minimizing misclassification, likely to be nondifferential, of
exposure. Finally, the biological mechanisms accounting for the
association between tramadol use and the risk of hip fracture
have not been fully understood; thus, future studies are war-
ranted to elucidate such an association.
Clinical implications
Pain is highly prevalent among the elderly population. In parallel
to the aging process of the society, both frailty and chronic dis-
eases involving pain are likely to increase. Owing to the adverse
effects of commonly used NSAIDs (ie, their cardiovascular, gas-
trointestinal, or renal risks) and safety concerns of traditional opi-
oids (ie, dependence and increased mortality), tramadol has
been considered as an alternative pain relief medication.(15–18)
Several professional organizations have strongly or conditionally
recommended tramadol as the first-line therapy for the treat-
ment of osteoarthritis,(45,46) Grade A for management of pain in
patients with fibromyalgia,(47,48) or the second-line therapy for
chronic low-back pain patients with an inadequate response to
nonpharmacologic treatments,(49) and its use has been increas-
ing rapidly over the past decades.(12,13,50,51) Although the HR
value of tramadol versus naproxen in men (2.46) is larger than
that in women (1.45), the rate difference in men (1.38/1000
person-years) is closer to that observed in women (1.05/1000
person-years). The large difference in HRs observed in men and
women is likely due to relatively low risk of hip fracture in men
who were initially prescribed naproxen. Considering the signifi-
cant impact of hip fracture on morbidity, mortality, and health
care cost,(52) our results point to the need to consider tramadol’s
associated risk of fracture in clinical practice and treatment
guidelines.
In conclusion, in this population-based cohort study, we
found that the initiation of tramadol was associated with a
higher risk of hip fracture than the initiation of codeine and com-
monly used NSAIDs.
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